Literature DB >> 8632927

Pulmonary administration of vasoactive substances by perfluorochemical ventilation.

M R Wolfson1, J S Greenspan, T H Shaffer.   

Abstract

OBJECTIVES: Therapeutic management of respiratory distress syndrome, pneumonia, and pulmonary hypertension includes delivery of biologically active agents to the neonatal lung. However, mechanical abnormalities of the lung, intrapulmonary shunting, ventilation-perfusion mismatching, and elevated surface tension impede effective systemic or intratracheal delivery of agents to the lung during conventional gas ventilation. The objective of this study was to test the hypothesis that perfluorochemical (PFC) liquid ventilation can be used for pulmonary administration of vasoactive drugs (PAD) and to compare these responses to those elicited with intravascular (IV) administration during tidal liquid ventilation.
METHODS: Cardiovascular responses of 16 preterm and neonatal lambs to randomized doses of acetylcholine, epinephrine, and priscoline were studied. Physiologic gas exchanged and acid-base balance were maintained using previously described tidal liquid ventilation techniques. In subgroups of animals, the distribution pattern of carbon 1- and choline 14-labeled dipalmitoylphosphatidylcholine (14C-DPPC) in saline and the responses to priscoline after hypoxia-induced pulmonary hypertension and hypoxemia administered during liquid ventilation were studied.
RESULTS: Dose-response curves for PAD and IV administration demonstrated progressive, dose-dependent, cholinergic responses to acetylcholine (decreased mean systemic arterial pressure [MAP] and heart rate), sympathomimetic responses to epinephrine (increased MAP and heart rate), and alpha-adrenergic blockade responses to priscoline (decreased MAP and mean pulmonary arterial pressure). Compared with IV administration, PAD of priscoline resulted in a significantly greater decrease in pulmonary relative to systemic arterial pressure; this response was potentiated by hypoxia, reduced pulmonary pressures to near normal values, and improved oxygenation. The 14C-DPPC in saline was distributed relatively homogeneously throughout the lung by PAD, with 80% of the lung pieces receiving amounts of 14C-DPPC with +/-20% of the mean value.
CONCLUSIONS: This study demonstrates that vasoactive agents can be delivered to the lung directly by PAD during PFC liquid ventilation. The inherent advantages of this method relate to the physical properties of PFC liquid ventilation as a vehicle (respiratory gas solubility, low surface tension-enhancing distribution, and inertness precluding interaction) and physiological properties of the lung as an exchanger.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8632927

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  6 in total

1.  Liquid ventilation.

Authors:  Qutaiba A Tawfic; Rajini Kausalya
Journal:  Oman Med J       Date:  2011-01

2.  Liquid dose pulmonary instillation of gentamicin PulmoSpheres formulations: tissue distribution and pharmacokinetics in rabbits.

Authors:  D J Smith; L M Gambone; T Tarara; D R Meays; L A Dellamary; C M Woods; J Weers
Journal:  Pharm Res       Date:  2001-11       Impact factor: 4.200

3.  Encapsulation and release of Amphotericin B from an ABC triblock fluorous copolymer.

Authors:  Jun-Pil Jee; Aaron McCoy; Sandro Mecozzi
Journal:  Pharm Res       Date:  2011-07-08       Impact factor: 4.200

Review 4.  Administration of Drugs/Gene Products to the Respiratory System: A Historical Perspective of the Use of Inert Liquids.

Authors:  Deepthi Alapati; Thomas H Shaffer
Journal:  Front Physiol       Date:  2022-05-10       Impact factor: 4.755

5.  High vapor pressure perfluorocarbons cause vesicle fusion and changes in membrane packing.

Authors:  Berenice Venegas; Marla R Wolfson; Peter H Cooke; Parkson Lee-Gau Chong
Journal:  Biophys J       Date:  2008-08-08       Impact factor: 4.033

6.  Perfluorochemical-facilitated plasminogen activator delivery to the airways: A novel treatment for inhalational smoke-induced acute lung injury.

Authors:  Marla R Wolfson; Perenlei Enkhbaatar; Satoshi Fukuda; Christina L Nelson; Robert O Williams; Soraya Hengsawas Surasarang; Sawittree Sahakijpijarn; Gennaro Calendo; Andrey A Komissarov; Galina Florova; Krishna Sarva; Steven I Idell; Thomas H Shaffer
Journal:  Clin Transl Med       Date:  2020-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.